Skip to Main Content

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Conditions

Brain and Nervous System

Phase II

What is the purpose of this trial?

This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

  • Trial with
    Alliance Cooperative Group
  • Start Date
    10/27/2019
  • End Date
    12/30/2021
Trial Image

For more information about this study, contact:

Kristin Fleischmann

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/29/2019
  • Study HIC
    #2000026111